NASDAQ:AKAO - Achaogen Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Achaogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKAO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKAO

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Achaogen in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for AKAO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Achaogen. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2019Needham & Company LLCReiterated RatingHoldLow
2/21/2019HC WainwrightReiterated RatingHold$2.00High
2/15/2019MizuhoReiterated RatingHold$3.00High
11/13/2018SunTrust BanksReiterated RatingBuy ➝ Hold$10.00 ➝ $3.00Medium
11/12/2018HC WainwrightReiterated RatingBuy ➝ Neutral$19.00 ➝ $3.00High
11/12/2018WedbushDowngradeOutperform ➝ Neutral$17.00 ➝ $3.00High
11/9/2018GabelliDowngradeBuy ➝ HoldHigh
11/9/2018Stifel NicolausDowngradeBuy ➝ HoldHigh
11/9/2018CowenDowngradeOutperform ➝ Market PerformHigh
11/9/2018MizuhoDowngradeBuy ➝ NeutralHigh
11/6/2018MizuhoReiterated RatingBuy ➝ Neutral$8.00 ➝ $8.00Low
8/20/2018SunTrust BanksLower Price TargetBuy$16.00 ➝ $10.00Low
8/7/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$14.00 ➝ $22.00Medium
8/7/2018Needham & Company LLCDowngradeBuy ➝ HoldMedium
7/27/2018CowenReiterated RatingBuyLow
6/27/2018WedbushLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.00High
5/7/2018GuggenheimDowngradeBuy ➝ Neutral$17.00High
5/4/2018SunTrust BanksLower Price TargetBuy$16.00High
5/3/2018MizuhoReiterated RatingBuyHigh
4/30/2018Needham & Company LLCReiterated RatingBuy$20.00High
4/30/2018HC WainwrightReiterated RatingBuy$19.00 ➝ $29.00High
3/4/2018SVB LeerinkReiterated RatingOutperformLow
3/1/2018HC WainwrightLower Price TargetBuy ➝ Buy$31.00 ➝ $29.00High
2/28/2018William BlairReiterated RatingOutperformHigh
2/28/2018Stifel NicolausLower Price TargetBuy ➝ Buy$27.00 ➝ $23.00Medium
2/28/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$29.00 ➝ $20.00Medium
2/14/2018WedbushReiterated RatingPositive ➝ Outperform$28.00 ➝ $22.00High
2/7/2018HC WainwrightBoost Price TargetBuy ➝ Buy$25.00 ➝ $31.00Medium
1/10/2018GuggenheimReiterated RatingBuy$14.00High
1/3/2018MizuhoReiterated RatingBuy$28.00High
1/3/2018SunTrust BanksLower Price TargetBuy$27.00High
11/30/2017MizuhoReiterated RatingBuy$28.00High
11/9/2017Stifel NicolausLower Price TargetBuy ➝ Buy$30.00 ➝ $27.00N/A
11/9/2017HC WainwrightReiterated RatingPositive ➝ Buy$25.00N/A
11/9/2017MizuhoReiterated RatingBuy$28.00N/A
10/30/2017MizuhoReiterated RatingBuy$28.00N/A
10/24/2017GuggenheimInitiated CoverageBuy$17.00N/A
10/9/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$28.00 ➝ $22.00N/A
9/28/2017MizuhoReiterated RatingBuy$28.00Medium
9/6/2017MizuhoInitiated CoverageBuy$28.00High
8/4/2017Stifel NicolausReiterated RatingBuy$30.00High
6/15/2017HC WainwrightInitiated CoverageBuy ➝ Buy$29.00Medium
5/15/2017CowenReiterated RatingOutperformN/A
5/9/2017Stifel NicolausReiterated RatingBuy ➝ Buy$28.00 ➝ $31.00Low
5/5/2017CowenReiterated RatingOutperformLow
4/24/2017WedbushReiterated RatingOutperform$28.00High
3/30/2017AegisDowngradeBuy ➝ Hold$29.00Low
3/15/2017WedbushReiterated RatingOutperform$28.00Medium
3/15/2017Needham & Company LLCReiterated RatingBuy$29.00Medium
3/15/2017AegisReiterated RatingBuy$39.00High
3/15/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$27.00 ➝ $28.00High
3/6/2017WedbushBoost Price TargetOutperform$23.00 ➝ $28.00N/A
3/2/2017WedbushReiterated RatingOutperform ➝ Outperform$23.00 ➝ $28.00N/A
3/2/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$19.00 ➝ $29.00N/A
2/23/2017AegisBoost Price TargetBuy$20.00 ➝ $29.00N/A
2/7/2017Stifel NicolausInitiated CoverageBuy$27.00N/A
1/31/2017WedbushInitiated CoverageOutperform$19.00 ➝ $23.00N/A
1/24/2017GuggenheimReiterated RatingBuy$30.00N/A
1/23/2017GuggenheimInitiated CoverageBuy ➝ PositiveN/A
1/4/2017SVB LeerinkInitiated CoverageOutperform$21.00N/A
12/15/2016WedbushReiterated RatingOutperform$10.00 ➝ $19.00N/A
12/13/2016CowenReiterated RatingBuyN/A
12/12/2016Needham & Company LLCUpgradeHold ➝ Buy$19.00N/A
11/28/2016CowenUpgradeMarket Perform ➝ OutperformN/A
11/22/2016WedbushReiterated RatingOutperform$10.00N/A
11/8/2016CowenReiterated RatingHoldN/A
11/8/2016WedbushReiterated RatingOutperform$10.00N/A
11/2/2016AegisInitiated CoverageBuy$10.00N/A
(Data available from 10/22/2016 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/22/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Achaogen logo
Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.11
Low: $0.11
High: $0.11

52 Week Range

Now: N/A

Volume

N/A

Average Volume

3,341,029 shs

Market Capitalization

$7.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Frequently Asked Questions

What sell-side analysts currently cover shares of Achaogen?

The following sell-side analysts have issued reports on Achaogen in the last year:
View the latest analyst ratings for AKAO.

What is the current price target for Achaogen?

0 Wall Street analysts have set twelve-month price targets for Achaogen in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Achaogen in the next year.
View the latest price targets for AKAO.

What is the current consensus analyst rating for Achaogen?

Achaogen currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AKAO.

How do I contact Achaogen's investor relations team?

Achaogen's physical mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is 650-800-3636 and its investor relations email address is [email protected] The official website for Achaogen is www.achaogen.com.